^
    Back
    Association details:
    Biomarker:BRAF mutation + TERT overexpression
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancers (Basel)
    Title:

    TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro

    Published date:
    05/24/2023
    Excerpt:
    A375RES and SkMel28RES showed, respectively, a 20- to 32-fold increased resistance to vemurafenib and a 45- to 55-fold increased resistance to cobimetinib in comparison to parental cell lines....The mRNA of expression of TERT was increased significantly in A375RES and SkMel28RES as compared to parental cells.
    DOI:
    10.3390/cancers15112888